Expression of estrogen and progesterone receptors, HER2 protein and Ki-67 proliferation index in breast carcinoma in both tumor tissue and tissue microarray.

Hacısalihoğlu U. P., Dogan M. A.

Biotechnic & histochemistry : official publication of the Biological Stain Commission, cilt.97, sa.4, ss.298-305, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 97 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/10520295.2021.1973102
  • Dergi Adı: Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.298-305
  • Anahtar Kelimeler: Breast, cancer, estrogen receptors, HER-2, human, Ki-67, progesterone receptors, tissue microarray, CANCER AMERICAN SOCIETY, IN-SITU HYBRIDIZATION, CLINICAL ONCOLOGY/COLLEGE, GENE AMPLIFICATION, KI67 EXPRESSION, CONCORDANCE, SECTIONS, CLASSIFICATION, TECHNOLOGY, VALIDATION
  • İstanbul Üniversitesi Adresli: Evet

Özet

ABSTRACT

Breast cancer treatment is tailored to molecular subtypes, which are classified by cell type and by presence of estrogen and progesterone receptors, HER2 overexpression and Ki-67 proliferation index. In routine pathological practice, these markers are detected in tumor tissue using immunohistochemistry, which requires four immunohistochemical antibodies for each patient. We developed a new tissue microarray procedure using a punch device with a 6 mm core diameter. The presence of estrogen and progesterone receptors, HER2 expression and the Ki-67 proliferation index of tumor tissues of 50 breast carcinoma patients had been determined using the conventional approach. We created three tissue microarray blocks, each containing samples from 14 main tumor tissues. One tissue microarray block was created with samples taken from eight main tumor tissues. Sections were cut from the four blocks and subjected to immunohistochemical staining; the original samples and the microarrays then were compared. We found significant agreement between estrogen receptor, progesterone receptor and HER-2 expression as well as Ki-67 proliferation index status of the original tumor tissues and the tissue microarray. Our tissue microarray technique using a single 6 mm core is a reliable and cost-effective method for determining estrogen and progesterone receptors, HER-2 status and Ki-67 proliferation index levels in patients with early breast carcinoma.